2 completed, 2 terminated, 1 unknown. 3 Phase 3, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 3 | Completed 1, Terminated 1, Unknown 1 |
| Phase 2 | 2 | Completed 1, Terminated 1 |
Follow Diffuse Cerebral Sclerosis of Schilder: new trials by email Literature Review of Diffuse Cerebral Sclerosis of Schilder trials Research Report on Diffuse Cerebral Sclerosis of Schilder
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Safety Study for Previously Treated Vatiquinone (PTC743) Participants With Inherited Mitochondrial Disease Vatiquinone - Inherited Mitochondrial Disease | Phase 3 | Completed | PTC Therapeutics | 101 | 2022-06-22 | 2025-12-22 |
| A Study to Evaluate Efficacy and Safety of Vatiquinone for Treating Mitochondrial Disease in Participants With Refractory Epilepsy Vatiquinone, Placebo - Mitochondrial Diseases, Drug Resistant Epilepsy | Phase 2 / Phase 3 | Terminated | PTC Therapeutics | 68 | 2020-09-28 | 2026-03-31 |
| Alpers Huttenlocher Natural History Study Alpers Huttenlocher Syndrome | Terminated | Columbia University | 2 | 2014-01-01 | 2022-08-01 | |
| Safety, Tolerability, Efficacy and Optimal Dose Finding Study of BAF312 in Patients With Relapsing-remitting Multiple Sclerosis BAF312, Placebo - Relapsing-remitting Multiple Sclerosis | Phase 2 | Completed | Novartis Pharmaceuticals | 297 | 2009-03-30 | 2020-01-13 |
| Phase III Randomized, Double-Blind, Sham-Controlled Study of Plasma Exchange for Acute Severe Attacks of Inflammatory Demyelinating Disease Refractory to Intravenous Methylprednisolone Plasma exchange - Acute Disseminated Encephalomyelitis, Devic's Syndrome | Phase 3 | Unknown | National Institute of Neurological Disorders and Stroke (NINDS) | 22 | 1995-01-01 | 2005-06-24 |
Drug Resistant Epilepsy (2) · Leigh Disease (2) · MELAS Syndrome (2) · MERRF Syndrome (2) · Multiple Sclerosis (2) · Neuromyelitis Optica (2) · Demyelinating Diseases (1) · Encephalomyelitis, Acute Disseminated (1) · Mental Disorders (1) · Mitochondrial Diseases (1) · Mitochondrial Encephalomyopathies (1) · Mitochondrial encephalopathy (1) · Multiple Sclerosis, Relapsing-Remitting (1) · Myelitis, Transverse (1)
Autoimmune Diseases (5) · Autoimmune Diseases of the Nervous System (5) · Brain Diseases (5) · Central Nervous System Diseases (5) · Demyelinating Autoimmune Diseases, CNS (5) · Immune System Diseases (5) · Leukoencephalopathies (5) · Nervous System Diseases (5) · Demyelinating Diseases (4) · Brain Diseases, Metabolic (2) · Brain Diseases, Metabolic, Inborn (2) · Carbohydrate Metabolism, Inborn Errors (2) · Cardiovascular Diseases (2) · Cerebral Small Vessel Diseases (2) · Cerebrovascular Disorders (2)
alpha-tocotrienol quinone (2) · Plasma Exchange (1) · siponimod (1)
PTC Therapeutics (2) · Columbia University (1) · National Institute of Neurological Disorders and Stroke (NINDS) (1) · Novartis Pharmaceuticals (1)
United States (4) · Italy (3) · Poland (3) · Spain (3) · Canada (2) · France (2) · Japan (2) · United Kingdom (2) · Finland (1) · Germany (1) · Hungary (1) · Norway (1) · Russia (1) · Sweden (1) · Switzerland (1)
Vinay Penematsa, MD (2) · Brian G. Weinshenker (1) · Michio Hirano, MD (1) · Russell Saneto, MD (1)
2008 (1), U54NS078059 (1)